Clinical Trial Update: Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of canakinumab in patients with hereditary periodic fever syndromes has completed, with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Periodic Fever Syndromes

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hereditary Periodic Fevers | Phase 3 | Status: COMPLETED | Results posted: 2017-03-17